See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements.
See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements.
See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements.
See Accompanying Notes to Unaudited Condensed
Consolidated Financial Statements.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Note 1 — Organization, Business and Basis
of Presentation:
Organization and Business
CorMedix Inc. (“CorMedix” or
the “Company”) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the
prevention and treatment of infectious and inflammatory diseases. The Company’s primary focus is on the development of its
lead product candidate, Neutrolin®, for potential commercialization in the United States (“U.S.”) and other key
markets. The Company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is a novel anti-infective
solution (a formulation of taurolidine 1.35%, citrate 3.5%, and heparin 1000 u/ml) intended for the reduction and prevention of
catheter-related infections and thrombosis in patients requiring central venous catheters (“CVCs”) in clinical settings
such as hemodialysis, critical/intensive care, and oncology. Infection and thrombosis represent key complications among hemodialysis,
critical care/intensive care and cancer patients with CVCs. These complications can lead to treatment delays and increased costs
to the healthcare system when they occur due to hospitalizations, need for intravenous (“IV”) antibiotic treatment,
long-term anticoagulation therapy, removal/replacement of the CVC, related treatment costs and increased mortality. The Company
believes Neutrolin addresses a significant unmet medical need and a potential large market opportunity.
In late 2013, the Company met with the U.S.
Food and Drug Administration (“FDA”), to determine the pathway for U.S. marketing approval of Neutrolin as a new drug
to prevent catheter-related blood stream infections (“CRBSIs”) in patients with end stage renal disease who are receiving
hemodialysis through a CVC. In January 2015, the FDA designated Neutrolin as Fast Track, which is a program designed to facilitate
development of drugs that are intended to address an unmet medical need and provides eligibility for priority review of the marketing
application. Also, in January 2015, the FDA designated Neutrolin as a Qualified Infectious Disease Product (“QIDP”),
which provides an additional five years of marketing exclusivity that is added to the five years granted to a New Chemical Entity
upon approval of a New Drug Application (“NDA”).
The Company launched its Phase 3 clinical
trial LOCK-IT-100 in patients with hemodialysis catheters in the U.S. in December 2015. The clinical trial was a multicenter,
double-blind study to demonstrate the safety and effectiveness of Neutrolin compared to the standard of care, heparin, in preventing
CRBSIs. The primary endpoint for the trial assessed the incidence of CRBSI and time to CRBSI for each study subject. Secondary
endpoints were catheter patency, which was defined as required use of tissue plasminogen activating factor (“tPA”)
or removal of catheter due to dysfunction, and removal of catheter for any reason.
In July 2018, 28 potential cases of CRBSI
were identified in LOCK-IT-100 that occurred through early December 2017. As previously agreed with the FDA, an interim efficacy
analysis was performed. Based on these first 28 cases, there was a highly statistically significant 72% reduction in CRBSI by
Neutrolin relative to the active control of heparin (p=0.0034). Because the pre-specified level of statistical significance was
reached for the primary endpoint and efficacy had been demonstrated with no safety concerns, the study was terminated early. Following
discussions with the FDA, the Company proceeded with an orderly termination of LOCK-IT-100. The study had continued enrolling
and treating subjects until study termination, and the final efficacy and safety analyses were based on a total of 795 subjects.
In late January 2019, the Company announced
the topline results of the full data set of LOCK-IT-100. In a total of 41 cases, there was a 71% reduction in CRBSI by Neutrolin
relative to the heparin control, which was highly statistically significant (p=0.0006), with a good safety profile.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
The FDA granted the Company’s request
for a rolling submission and review of the NDA, which is designed to expedite the approval process for products being developed
to address an unmet medical need. Although the FDA usually requires two pivotal clinical trials to provide substantial evidence
of safety and effectiveness for approval of the NDA, the FDA will in some cases accept one adequate and well-controlled trial,
where it is a large multicenter trial with a broad range of subjects and study sites that has demonstrated a clinically meaningful
and statistically very persuasive effect on a disease with potentially serious outcome. In March 2020, the Company began the modular
submission process for the NDA for Neutrolin for the prevention of CRBSI in hemodialysis patients. The Company has not been informed
of any delays by the FDA in the review of the NDA, but the FDA has limited international and domestic travel due to COVID-19,
and pre-approval inspections are required for manufacturing sites. The Company still believes that it is on schedule for the potential
approval of the NDA during the second half of 2020, however, disruptions incurred by the FDA may result in a delay.
The FDA also agreed that the Company could
request consideration of Neutrolin for approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (“LPAD”).
LPAD, passed as part of the 21st Century Cures Act, is a new program intended to expedite the development and approval
of certain antibacterial and antifungal drugs to treat serious or life-threatening infections in limited populations of patients.
Given that the LPAD pathway provides for a streamlined clinical development program for a limited population that may involve
smaller, shorter, or fewer clinical trials, we believe that LPAD will provide additional flexibility for the FDA to approve Neutrolin
to prevent CRBSIs in the limited population of patients with end-stage renal disease receiving hemodialysis through a central
venous catheter.
In March 2020, the Company was granted by the
FDA a deferral under the Pediatric Research Equity Act (“PREA”) that requires sponsors to conduct pediatric studies
for NDAs for a new active ingredient, such as taurolidine in Neutrolin, unless a waiver or deferral is obtained from the FDA. A
deferral acknowledges that a pediatric assessment is required but permits the applicant to submit the pediatric assessment after
the submission of an NDA. CorMedix has made a commitment to conduct the pediatric study after approval of the NDA for use in adult
hemodialysis patients. Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which
would provide an additional six months of marketing exclusivity. Neutrolin would then have the potential to receive a total marketing
exclusivity period of 10.5 years.
In the European Union (“EU”),
Neutrolin is regulated as a Class 2 medical device. In July 2013, the Company received CE Mark approval for Neutrolin. In December 2013,
the Company started commercial sales of Neutrolin in Germany for the prevention of CRBSI, and maintenance of catheter patency
in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access. To date, Neutrolin is registered
and may be sold in certain European Union and Middle Eastern countries for such treatment.
In September 2014, the TUV-SUD and The
Medicines Evaluation Board of the Netherlands (“MEB”), granted a label expansion for Neutrolin for these same expanded
indications for the EU. In December 2014, the Company received approval from the Hessian District President in Germany to expand
the label to include use in oncology patients receiving chemotherapy, IV hydration and IV medications via CVC. The expansion also
adds patients receiving medication and IV fluids via CVC in intensive or critical care units (cardiac care unit, surgical care
unit, neonatal critical care unit, and urgent care centers). An indication for use in total parenteral nutrition was also approved.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
In addition to Neutrolin, the Company is
sponsoring a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare orphan pediatric
tumors. In February 2018, the FDA granted orphan drug designation to taurolidine for the treatment of neuroblastoma in children.
The Company may seek one or more strategic partners or other sources of capital to help with the development and commercialization
of taurolidine for the treatment of neuroblastoma in children. The Company is also evaluating opportunities for the possible expansion
of taurolidine as a platform compound for use in certain medical devices. Patent applications have been filed in several indications,
including wound closure, surgical meshes, and wound management. Based on initial feasibility work, the Company is advancing pre-clinical
studies for taurolidine-infused surgical meshes, suture materials and hydrogels. The Company will seek to establish development/commercial
partnerships as these programs advance.
In December 2019, the novel coronavirus disease,
COVID-19, was identified in Wuhan, China. This virus has been declared a pandemic and has spread to multiple global regions. The
outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses
and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended;
and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and
services, such as travel, has fallen. In response to the COVID-19 outbreak, “shelter in place” orders and other public
health guidance measures have been implemented across much of the United States, Europe and Asia, including in the locations of
the Company’s offices, clinical trial sites, key vendors and partners. The Company’s clinical development program timelines
may be negatively affected by COVID-19, which could materially and adversely affect its business, financial condition and results
of operations.
Basis of Presentation
The accompanying unaudited
condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in
the United States of America (“GAAP”) for interim financial information and with the instructions for Form 10-Q and
Article 8 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all information
and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited
condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary
to fairly state the interim results. Interim operating results are not necessarily indicative of results that may be expected
for the full year ending December 31, 2020 or for any subsequent period. These unaudited condensed consolidated financial statements
should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the
Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 16,
2020. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited financial
statements included in such Form 10-K.
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting
Standards Board (“FASB”) issued new guidance which replaces the incurred loss impairment methodology in current GAAP
with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable
information to inform credit loss estimates. This adoption on January 1, 2020 did not have a material impact on the Company’s
condensed consolidated financial statements.
In August 2018, the FASB issued a new guidance
which modifies the disclosure requirements on fair value measurements. The guidance is effective for the Company beginning in
the first quarter of fiscal year 2020. Early adoption is permitted. This adoption on January 1, 2020 did not have a material impact
on the Company’s condensed consolidated financial statements.
In November 2018, the FASB issued new guidance
to clarify the interaction between the authoritative guidance for collaborative arrangements and revenue from contracts with customers.
The new guidance clarifies that, when the collaborative arrangement participant is a customer in the context of a unit-of-account,
revenue from contracts with customers guidance should be applied, adds unit-of-account guidance to collaborative arrangements
guidance, and requires, that in a transaction with a collaborative arrangement participant who is not a customer, presenting the
transaction together with revenue recognized under contracts with customers is precluded. The guidance is effective for the Company
beginning in the first quarter of fiscal year 2020. Early adoption is permitted. This adoption on January 1, 2020 did not have
a material impact on the Company’s condensed consolidated financial statements.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
In November 2019, the FASB issued new guidance
which requires that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in
FASB’s Accounting Standards Codification (“ASC”) 718. The guidance is effective for the Company beginning in
the first quarter of fiscal year 2020. Early adoption is permitted. This adoption on January 1, 2020 did not have a material impact
on the Company’s condensed consolidated financial statements.
Recently Issued Authoritative Pronouncements
In December 2019, the FASB issued new guidance
which removes certain exceptions to the general principles of the accounting for income taxes and also improves consistent application
of and simplification of other areas when accounting for income taxes. The guidance is effective for the company beginning in
the first quarter of fiscal year 2021. Early adoption is permitted. The Company is assessing the impact of adopting this guidance
on its consolidated financial statements.
Note 2 — Summary of Significant Accounting
Policies:
Liquidity and Uncertainties
The financial statements have been prepared
in conformity with GAAP which contemplate continuation of the Company as a going concern. To date, the Company’s commercial
operations have not generated sufficient revenues to enable profitability. As of March 31, 2020, the Company had an accumulated
deficit of $201.0 million, and incurred losses from operations of $5.6 million and $5.2 million for the three months ended March
31, 2020 and 2019, respectively. The Company currently estimates that as of March 31, 2020 it has sufficient cash, cash equivalents
and short-term investments on hand to fund operations through the second quarter of 2021, after taking into consideration, the
receipt of net proceeds from the sale of its net operating loss carryforwards, the refund of the advance payment of the NDA application
fee, additional costs related to the submission of the NDA for Neutrolin and initial preparations for commercial launch. The Company
currently anticipates that the FDA marketing approval for Neutrolin could be received in the second half of 2020.
In April 2020, the Company received approximately
$5.2 million, net of expenses, from the sale of a portion of its unused New Jersey net operating losses (“NOL”). The
NOL was sold through the State of New Jersey’s Economic Development Authority’s New Jersey Technology Business Tax
Certificate Transfer program, which allowed the Company to sell approximately $5.5 million of its total $6.0 million in available
NOL tax benefits for the state fiscal year 2019.
In April 2020, the Company received from
the FDA the refund for the NDA application fee in the amount of $2.9 million. The Company met the conditions of the Federal Food,
Drug, and Cosmetic Act for the small business waiver of the user fees and its request for a waiver of an application user fee
was granted by the FDA.
The Company’s continued operations will
depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic
relationships, or out-licensing of its products, to commercially launch Neutrolin upon NDA approval, and until profitability is
achieved, if ever. Management can provide no assurances that such financing or strategic relationships will be available on acceptable
terms, or at all. At March 31, 2020, the Company had approximately $2.1 million available under its current ATM program and
$30.3 million available under its current shelf registration statement for the issuance of equity, debt or equity-linked securities
unrelated to the current ATM program.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
The Company’s operations are subject
to a number of other factors that can affect its operating results and financial condition. Such factors include, but are not
limited to: the ability to obtain regulatory approval to market the Company’s products; ability to manufacture successfully;
competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products;
the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products;
the results of clinical testing and trial activities of the Company’s product candidates; and the Company’s ability
to raise capital to support its operations.
Use of Estimates
The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts
of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Basis of Consolidation
The condensed consolidated financial statements
include the accounts of the Company and CorMedix Europe GmbH, its wholly owned subsidiary. All significant intercompany accounts
and transactions have been eliminated in consolidation.
Financial Instruments
Financial instruments
that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term
investments. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts, the balances
of which, at times, may exceed federally insured limits.
The following table
is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and
disclosure of financial instruments as shown on the Company’s consolidated statement of cash flows:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
Cash and cash equivalents
|
|
$
|
12,204,569
|
|
|
$
|
16,350,237
|
|
Restricted cash
|
|
|
171,593
|
|
|
|
174,950
|
|
Total cash, cash equivalents and restricted cash
|
|
$
|
12,376,162
|
|
|
$
|
16,525,187
|
|
The appropriate classification of marketable
securities is determined at the time of purchase and reevaluated as of each balance sheet date. Investments in marketable debt
classified as available-for-sale and equity securities are reported at fair value. Fair value is determined using quoted market
prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs
that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Changes in fair value that are considered temporary are reported in the condensed consolidated statement of operations. Realized
gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense).
For declines in the fair value of equity securities that are considered other-than-temporary, impairment losses are charged to
other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments,
including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at March 31,
2020 or December 31, 2019.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
The Company’s marketable securities are
highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original
maturities of more than 90 days. As of March 31, 2020 and December 31, 2019, all of the Company’s investments had
contractual maturities of less than one year. As of March 31, 2020, no allowance for credit loss was recorded. The following
table summarizes the amortized cost, unrealized gains and losses and the fair value at March 31, 2020 and December 31,
2019:
|
|
Amortized Cost
|
|
|
Gross Unrealized Losses
|
|
|
Gross Unrealized Gains
|
|
|
Fair Value
|
|
March 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds included in Cash Equivalents
|
|
$
|
1,567,300
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,567,300
|
|
U.S. Government Agency Securities
|
|
|
1,697,380
|
|
|
|
-
|
|
|
|
8,249
|
|
|
|
1,705,629
|
|
Corporate Securities
|
|
|
7,348,280
|
|
|
|
(15,384
|
)
|
|
|
710
|
|
|
|
7,333,606
|
|
Commercial Paper
|
|
|
1,942,894
|
|
|
|
(65
|
)
|
|
|
1,126
|
|
|
|
1,943,955
|
|
Subtotal
|
|
|
10,988,554
|
|
|
|
(15,449
|
)
|
|
|
10,085
|
|
|
|
10,983,190
|
|
Total March 31, 2020
|
|
$
|
12,555,854
|
|
|
$
|
(15,449
|
)
|
|
$
|
10,085
|
|
|
$
|
12,550,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds included in Cash Equivalents
|
|
$
|
3,472,043
|
|
|
$
|
-
|
|
|
$
|
51
|
|
|
$
|
3,472,094
|
|
U.S. Government Agency Securities
|
|
|
2,691,091
|
|
|
|
(42
|
)
|
|
|
869
|
|
|
|
2,691,918
|
|
Corporate Securities
|
|
|
6,058,265
|
|
|
|
(1,438
|
)
|
|
|
440
|
|
|
|
6,057,267
|
|
Commercial Paper
|
|
|
3,234,583
|
|
|
|
(16
|
)
|
|
|
405
|
|
|
|
3,234,972
|
|
Subtotal
|
|
|
11,983,939
|
|
|
|
(1,496
|
)
|
|
|
1,714
|
|
|
|
11,984,157
|
|
Total December 31, 2019
|
|
$
|
15,455,982
|
|
|
$
|
(1,496
|
)
|
|
$
|
1,765
|
|
|
$
|
15,456,251
|
|
Fair Value Measurements
The Company’s financial instruments
recorded in the condensed consolidated balance sheets include cash and cash equivalents, accounts receivable, investment securities,
accounts payable and accrued expenses. The carrying value of certain financial instruments, primarily cash and cash equivalents,
accounts receivable, accounts payable, and accrued expenses approximate their estimated fair values based upon the short-term
nature of their maturity dates.
The Company categorizes its financial instruments
into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair
value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority
to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the
category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.
Financial assets recorded at fair value on the Company’s condensed consolidated balance sheets are categorized as follows:
|
●
|
Level 1 inputs—Observable inputs that reflect quoted
prices (unadjusted) for identical assets or liabilities in active markets.
|
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
|
●
|
Level 2 inputs— Significant other observable inputs
(e.g., quoted prices for similar items in active markets, quoted prices for identical
or similar items in markets that are not active, inputs other than quoted prices that
are observable such as interest rate and yield curves, and market-corroborated inputs).
|
|
●
|
Level 3 inputs—Unobservable inputs for the asset
or liability, which are supported by little or no market activity and are valued based
on management’s estimates of assumptions that market participants would use in
pricing the asset or liability.
|
The following table provides the carrying
value and fair value of the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2020
and December 31, 2019:
|
|
Carrying Value
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
March 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds and Cash Equivalents
|
|
$
|
1,567,300
|
|
|
$
|
1,567,300
|
|
|
$
|
-
|
|
|
$
|
-
|
|
U.S. Government Agency Securities
|
|
|
1,705,629
|
|
|
|
1,705,629
|
|
|
|
-
|
|
|
|
-
|
|
Corporate Securities
|
|
|
7,333,606
|
|
|
|
-
|
|
|
|
7,333,606
|
|
|
|
-
|
|
Commercial Paper
|
|
|
1,943,955
|
|
|
|
-
|
|
|
|
1,943,955
|
|
|
|
-
|
|
Subtotal
|
|
|
10,983,190
|
|
|
|
1,705,629
|
|
|
|
9,277,561
|
|
|
$
|
-
|
|
Total March 31, 2020
|
|
$
|
12,550,490
|
|
|
$
|
3,272,929
|
|
|
$
|
9,277,561
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds and Cash Equivalents
|
|
$
|
3,472,094
|
|
|
$
|
3,472,094
|
|
|
$
|
-
|
|
|
$
|
-
|
|
U.S. Government Agency Securities
|
|
|
2,691,918
|
|
|
|
2,691,918
|
|
|
|
-
|
|
|
|
-
|
|
Corporate Securities
|
|
|
6,057,267
|
|
|
|
-
|
|
|
|
6,057,267
|
|
|
|
-
|
|
Commercial Paper
|
|
|
3,234,972
|
|
|
|
-
|
|
|
|
3,234,972
|
|
|
|
-
|
|
Subtotal
|
|
|
11,984,157
|
|
|
|
2,691,918
|
|
|
|
9,292,239
|
|
|
|
-
|
|
Total December 31, 2019
|
|
$
|
15,456,251
|
|
|
$
|
6,164,012
|
|
|
$
|
9,292,239
|
|
|
$
|
-
|
|
Foreign Currency Translation
and Transactions
The condensed consolidated financial statements
are presented in U.S. Dollars (“USD”), the reporting currency of the Company. For the financial statements of the
Company’s foreign subsidiary, whose functional currency is the EURO, foreign currency asset and liability amounts, are translated
into USD at end-of-period exchange rates. Foreign currency income and expenses are translated at average exchange rates in effect
during the period in which the income and expenses were recognized. Translation gains and losses are included in other comprehensive
income (loss).
The Company has intercompany loans between
the parent company based in New Jersey and its German subsidiary. The intercompany loans outstanding are not expected to be repaid
in the foreseeable future and unrealized foreign exchange movements related to long-term intercompany loans are recognized in
other comprehensive income (loss).
Foreign currency exchange transaction gain
(loss) is the result of re-measuring transactions denominated in a currency other than the functional currency of the entity recording
the transaction.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Restricted Cash
As of March 31, 2020, and December 31,
2019, the Company has restricted cash in connection with the patent and utility model infringement proceedings against TauroPharm
(see Note 4). The Company was required by the District Courts of Mannheim to provide security deposit of an aggregate of approximately
€110,000 to cover legal fees in the event TauroPharm is entitled to reimbursement of these costs. The company furthermore
had to provide a deposit in the amount of €36,000 and €10,000 for the first and second instances, respectively, in connection
with the unfair competition proceedings in Cologne.
Prepaid Research and Development and Other Prepaid Expenses
Prepaid expenses consist of payments made
in advance to vendors relating to service contracts for clinical trial development, manufacturing, preclinical development and
insurance policies. These advanced payments are amortized to expense either as services are performed or over the relevant service
period using the straight-line method.
Other prepaid expenses consist of the following:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
Refundable regulatory fee
|
|
$
|
2,942,965
|
|
|
$
|
-
|
|
Insurance expense
|
|
|
246,464
|
|
|
|
244,828
|
|
Subscription fees
|
|
|
183,734
|
|
|
|
97,983
|
|
Software costs
|
|
|
104,597
|
|
|
|
10,081
|
|
Other
|
|
|
84,212
|
|
|
|
93,523
|
|
Total
|
|
$
|
3,561,972
|
|
|
$
|
446,415
|
|
The Company met the conditions of the Federal
Food, Drug, and Cosmetic Act for the small business waiver of the user fees and its request for a waiver of an application user
fee was granted by the FDA. On April 29, 2020, the refund in the amount of $2,942,965 was received from the FDA.
Inventories, net
Inventories are valued at the lower of
cost or net realizable value on a first in, first out basis. Inventories consist of raw materials (including labeling and packaging),
work-in-process, and finished goods, if any, for the Neutrolin product. Inventories consist of the following:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
Raw materials
|
|
$
|
6,893
|
|
|
$
|
6,893
|
|
Finished goods
|
|
|
418,178
|
|
|
|
461,735
|
|
Inventory reserve
|
|
|
(130,163
|
)
|
|
|
(130,163
|
)
|
Total
|
|
$
|
294,908
|
|
|
$
|
338,465
|
|
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Leases
The Company determines if an arrangement
is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion
of operating lease liabilities, and operating lease liabilities, net of current portion, on the condensed consolidated balance
sheet.
Operating lease ROU assets and operating
lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement
date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments. The Company’s lease
terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.
Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company has elected, as an accounting
policy, not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of
12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably
certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term.
The Company has also elected, as a practical
expedient, by underlying class of asset, not to separate lease components from non-lease components and, instead, account for
them as a single component.
Accrued Expenses
Accrued expenses consist
of the following:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
Professional and consulting fees
|
|
$
|
287,560
|
|
|
$
|
214,777
|
|
Accrued payroll and payroll taxes
|
|
|
660,243
|
|
|
|
1,287,047
|
|
Clinical trial related
|
|
|
2,455,141
|
|
|
|
2,435,953
|
|
Manufacturing development related
|
|
|
1,000,904
|
|
|
|
806,032
|
|
Other
|
|
|
67,047
|
|
|
|
56,677
|
|
Total
|
|
$
|
4,470,895
|
|
|
$
|
4,800,486
|
|
In December 2015, the Company contracted
a clinical research organization (“CRO”) to help the Company conduct its LOCK-IT-100 Phase 3 multicenter, double-blind,
randomized active control study to demonstrate the safety and effectiveness of Neutrolin in preventing catheter-related bloodstream
infections and blood clotting in subjects receiving hemodialysis therapy as treatment for end stage renal disease.
Through March 31, 2020, approximately $30.0
million of clinical trial expense has been recorded, of which approximately $27.4 million has been paid. During the quarters ended
March 31, 2020 and 2019, the Company recognized $22,000 and $517,000, respectively, in research and development expense related
to this agreement. At March 31, 2020, the Company had accrued approximately $2.5 million in accounts payable and accrued expenses.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Revenue Recognition
The Company recognizes
revenue in accordance with ASC 606, “Revenue from Contracts with Customers.” ASC 606 prescribes a five-step
model for recognizing revenue which includes (i) identifying contracts with customers; (ii) identifying performance obligations;
(iii) determining the transaction price; (iv) allocating the transaction price; and (v) recognizing revenue.
The Company recognizes net sales upon shipment
of product and upon meeting the five-step model prescribed by ASC 606 outlined above.
Loss Per Common Share
Basic loss per common
share excludes any potential dilution and is computed by dividing net loss by the weighted average number of common shares outstanding
during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts
to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared
in the earnings of the entity. However, since their effect is anti-dilutive, the Company has excluded potentially dilutive shares.
The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect
would be anti-dilutive.
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(Number of Shares of Common Stock Issuable)
|
|
Series C non-voting preferred stock
|
|
|
104,000
|
|
|
|
408,000
|
|
Series D non-voting preferred stock
|
|
|
-
|
|
|
|
295,848
|
|
Series E non-voting preferred stock
|
|
|
391,953
|
|
|
|
391,953
|
|
Series F non-voting preferred stock
|
|
|
-
|
|
|
|
2,469,137
|
|
Series G non-voting preferred stock
|
|
|
5,560,137
|
|
|
|
-
|
|
Shares issuable upon conversion of convertible debt
|
|
|
-
|
|
|
|
1,000,000
|
|
Restricted stock units
|
|
|
417
|
|
|
|
19,917
|
|
Shares issuable for payment of deferred board compensation
|
|
|
35,303
|
|
|
|
29,427
|
|
Shares underlying outstanding warrants
|
|
|
183,148
|
|
|
|
3,199,788
|
|
Shares underlying outstanding stock options
|
|
|
1,720,937
|
|
|
|
1,212,974
|
|
Total potentially dilutive shares
|
|
|
7,995,895
|
|
|
|
9,027,044
|
|
Stock-Based Compensation
Share-based compensation cost for stock
options granted to employees is measured at grant date using the Black-Scholes stock option pricing model in accordance with ASC
No. 718, “Compensation-Stock Compensation”, based on the estimated fair value of the award for options with
service or performance-based conditions and is recognized as expense over the requisite service period on a straight-line basis.
For stock options with performance-based vesting provisions, share-based compensation cost is recorded when the achievement of
the performance condition is probable.
Research and Development
Research and development costs are charged
to expense as incurred. Research and development include fees associated with operational consultants, contract clinical research
organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract
central testing laboratories, licensing activities, and allocated executive, human resources, facilities expenses and costs related
to the manufacturing of the product that could potentially be available to support the commercial launch prior to marketing approval.
The Company accrues for costs incurred as the services are being provided by monitoring the status of the activities and the invoices
received from its external service providers. Costs related to the acquisition of technology rights and patents for which development
work is still in process are charged to operations as incurred and considered a component of research and development expense.
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Note 3 — Stockholders’ Equity:
Common Stock
The Company is a party to a sales agreement
with B. Riley dated March 9, 2018 for the sale of up to $14.7 million of the Company’s common stock under the Company’s
ATM program, pursuant to a registration statement filed on March 9, 2018 for an aggregate of $70.0 million of the Company’s
securities, which became effective on April 16, 2018. In November 2018, the ATM program amount was increased by $25.0 million.
Under the ATM program, the Company may issue and sell common stock from time to time through B. Riley acting as agent, subject
to limitations imposed by the Company and subject to B. Riley’s acceptance, such as the number or dollar amount of shares
registered under the registration statement to which the offering relates. B. Riley is entitled to a commission of up to 3% of
the gross proceeds from the sale of common stock sold under the ATM program. At March 31, 2020, the Company has approximately
$2.1 million available under its current ATM program and $30.3 million available under its current shelf registration for the
issuance of equity, debt or equity-linked securities unrelated to the current ATM program.
During the three months ended March 31,
2020 and 2019, the Company sold 368,144 and 1,768,012 shares of common stock under the ATM program, respectively, and realized
net proceeds of approximately $2.5 million and $15.2 million, respectively.
During the quarter ended March 31, 2020,
the Company issued an aggregate of 91,500 shares of its common stock upon exercise of warrants, resulting in net proceeds to the
Company of $412,000.
During the quarter ended March 31, 2020,
the Company issued an aggregate of 2,073 shares of its common stock upon the vesting of restricted stock units issued to the Company’s
board of directors.
Preferred Stock
The Company is authorized to issue up to
2,000,000 shares of preferred stock in one or more series without stockholder approval. The Company’s board of directors
has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights,
conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Of the 2,000,000 shares
of preferred stock authorized, the Company’s board of directors has designated (all with par value of $0.001 per share)
the following:
|
|
As of March 31, 2020
|
|
|
As of December 31, 2019
|
|
|
|
Preferred Shares Outstanding
|
|
|
Liquidation Preference (Per Share)
|
|
|
Total Liquidation Preference
|
|
|
Preferred Shares Outstanding
|
|
|
Liquidation Preference (Per Share)
|
|
|
Total Liquidation Preference
|
|
Series C-3
|
|
|
52,000
|
|
|
$
|
10.00
|
|
|
$
|
520,000
|
|
|
|
52,000
|
|
|
$
|
10.00
|
|
|
$
|
520,000
|
|
Series E
|
|
|
89,623
|
|
|
$
|
49.20
|
|
|
$
|
4,409,452
|
|
|
|
89,623
|
|
|
$
|
49.20
|
|
|
$
|
4,409,452
|
|
Series G
|
|
|
100,000
|
|
|
$
|
187.36
|
|
|
$
|
18,736,452
|
|
|
|
100,000
|
|
|
$
|
187.36
|
|
|
$
|
18,736,452
|
|
Total
|
|
|
241,623
|
|
|
|
|
|
|
$
|
23,665,904
|
|
|
|
241,623
|
|
|
|
|
|
|
$
|
23,665,904
|
|
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Stock Options
During the three months ended March 31,
2020, the Company granted ten-year qualified and non-qualified stock options covering an aggregate of 380,234 shares of the Company’s
common stock under the 2019 Stock Incentive Plan. The weighted average exercise price of these options is $5.91 per share.
During the three months
ended March 31, 2020 and 2019, total compensation expense for stock options issued to employees, directors, officers and consultants
was $670,000 and $759,000, respectively.
As of March 31, 2020, there was approximately
$2,828,000 in total unrecognized compensation expense related to stock options granted, which expense will be recognized over
an expected remaining weighted average period of 1.6 years.
The fair value of each
stock option award estimated on the grant date is determined using the Black-Scholes option pricing model with the following assumptions,
for the three months ended March 31, 2020:
Expected term, years
|
|
|
5 - 10
|
|
Volatility
|
|
|
102.73% - 107.87%
|
|
Dividend yield
|
|
|
0.0%
|
|
Risk-free interest rate
|
|
|
1.16% - 1.67%
|
|
Weighted average grant date fair value of options granted during the period
|
|
|
$ 4.47
|
|
The Company estimated the expected term
of the stock options granted based on anticipated exercises in future periods. The expected term of the stock options granted
to consultants is based upon the full term of the respective option agreements. The expected stock price volatility for the Company’s
stock options is calculated based on the historical volatility since the initial public offering of the Company’s common
stock in March 2010. The expected dividend yield of 0.0% reflects the Company’s current and expected future policy for dividends
on the Company’s common stock. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve
in effect at the time of grant with a term consistent with the expected term of the Company’s awards which is 5 years for
employees and 10 years for non-employees.
The following table summarizes the Company’s
stock options activity and related information for the three months ended March 31, 2020:
|
|
Shares
|
|
|
Weighted Average
Exercise Price
|
|
|
Weighted Average
Remaining Contractual Term (Years)
|
|
|
Aggregate Intrinsic Value
|
|
Outstanding at beginning of period
|
|
|
1,376,394
|
|
|
$
|
8.98
|
|
|
|
6.8
|
|
|
$
|
1,232,545
|
|
Granted
|
|
|
380,234
|
|
|
$
|
5.91
|
|
|
|
|
|
|
$
|
-
|
|
Forfeited
|
|
|
(28,800
|
)
|
|
$
|
9.01
|
|
|
|
|
|
|
$
|
-
|
|
Expired
|
|
|
(6,891
|
)
|
|
$
|
12.53
|
|
|
|
|
|
|
$
|
-
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
$
|
-
|
|
Outstanding at end of period
|
|
|
1,720,937
|
|
|
$
|
8.28
|
|
|
|
7.1
|
|
|
$
|
205,943
|
|
Exercisable at end of period
|
|
|
1,037,899
|
|
|
$
|
8.94
|
|
|
|
5.8
|
|
|
$
|
156,570
|
|
CORMEDIX INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
The aggregate intrinsic value is calculated
as the difference between the exercise prices of the underlying options and the quoted closing price of the common stock of the
Company at the end of the reporting period for those options that have an exercise price below the quoted closing price. There
were no stock options exercised during the three months ended March 31, 2019.
Restricted Stock Units
During the three months ended March 31,
2020, the Company issued an aggregate of 2,073 shares of its common stock upon the vesting of RSUs issued to the Company’s
board of directors.
During the three months ended March 31,
2020 and 2019, compensation expense recorded for the RSUs was $7,000 and $50,000, respectively. Unrecognized compensation expense
for these RSUs amounted to $3,000. The expected weighted average period for the expense to be recognized is 0.18 years.
Warrants
During the three months ended March 31,
2020 and 2019, the Company issued an aggregate of 91,500 and 119,220 shares of its common stock upon exercise of warrants, respectively,
resulting in net proceeds to the Company of $412,000 and $620,000, respectively.
As
of March 31, 2020, there were 183,148 outstanding warrants with a weighted average exercise price of $4.96 per share and a weighted
average remaining contractual life of 2.4 years.
Note 4 — Commitments and Contingencies:
Contingency Matters
On September 9, 2014, the Company filed
in the District Court of Mannheim, Germany, a patent infringement action against TauroPharm GmbH and Tauro-Implant GmbH as well
as their respective CEOs (the “Defendants”) claiming infringement of the Company’s European Patent EP 1 814
562 B1, which was granted by the European Patent Office (the “EPO”) on January 8, 2014 (the “Prosl European
Patent”). The Prosl European Patent covers the formulation of taurolidine and citrate with low dose heparin in a catheter
lock solution for maintaining patency and preventing infection in hemodialysis catheters. In this action, the Company claims that
the Defendants infringe on the Prosl European Patent by manufacturing and distributing catheter locking solutions to the extent
they are covered by the claims of the Prosl European Patent. The Company believes that its patent is sound and is seeking injunctive
relief and raising claims for information, rendering of accounts, calling back, destruction and damages. Separately, TauroPharm
has filed an opposition with the EPO against the Prosl European Patent alleging that it lacks novelty and inventive step. The
Company cannot predict what other defenses the Defendants may raise, or the ultimate outcome of either of these related matters.
At present, the EPO has revoked the Prosl European Patent as invalid, and the Company has filed an appeal, which is currently
pending.
CORMEDIX
INC. AND SUBSIDIARY
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
In
the same complaint against the same Defendants, the Company also alleged an infringement (requesting the same remedies) of ND
Partners’ utility model DE 20 2005 022 124 U1 (the “Utility Model”), which the Company believes is fundamentally
identical to the Prosl European Patent in its main aspects and claims. The Court separated the two proceedings and the Prosl European
Patent and the Utility Model claims are now being tried separately. TauroPharm has filed a cancellation action against the Utility
Model before the German Patent and Trademark Office (the “German PTO”) based on the similar arguments as those in
the opposition against the Prosl European Patent.
On
March 27, 2015, the District Court held a hearing to evaluate whether the Utility Model has been infringed by TauroPharm in connection
with the manufacture, sale and distribution of its TauroLock-HEP100TM and TauroLock-HEP500TM products. A
hearing before the same court was held on January 30, 2015 on the separate, but related, question of infringement of the Prosl
European Patent by TauroPharm.
The Court issued its decisions on May 8, 2015,
staying both proceedings. In its decisions, the Court found that the commercialization by TauroPharm in Germany of its TauroLock
catheter lock solutions Hep100 and Hep500 infringes both the Prosl European Patent and the Utility Model and further that
there is no prior use right that would allow TauroPharm to continue to make, use or sell its product in Germany. However, the Court
declined to issue an injunction in favor of the Company that would preclude the continued commercialization by TauroPharm based
upon its finding that there is a sufficient likelihood that the EPO, in the case of the Prosl European Patent, or the German PTO,
in the case of the Utility Model, may find that such patent or utility model is invalid. Specifically, the Court noted the possible
publication of certain instructions for product use that may be deemed to constitute prior art. As such, the District Court determined
that it will defer any consideration of the request by the Company for injunctive and other relief until such time as the EPO or
the German PTO made a final decision on the underlying validity of the Prosl European Patent and the Utility Model. We expect that
the complaint regarding the infringement of the Utility Model will be dismissed now that the German PTO has voided the Utility
Model (see below). This does not, however, have a direct effect on the infringement proceedings concerning the Prosl European Patent.
The
opposition proceeding against the Prosl European Patent before the EPO is ongoing. The EPO held a hearing in the opposition proceeding
on November 25, 2015. In its preliminary consideration of the matter, the EPO (and the German PTO) had regarded the patent as
not inventive or novel due to publication of prior art. However, the EPO did not issue a decision at the end of the hearing but
adjourned the matter due to the fact that the panel was of the view that Claus Herdeis, one of the managing directors of TauroPharm,
had to be heard as a witness in a further hearing in order to close some gaps in the documentation presented by TauroPharm as
regards the publication of the prior art.
The
German PTO held a hearing in the validity proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmed
its preliminary finding that the Utility Model was invalid based upon prior publication of a reference to the benefits that may
be associated with adding heparin to a taurolidine based solution. The Company filed an appeal against the ruling on September
7, 2016. An oral hearing was held on September 17, 2019 in which the German Federal Patent Court affirmed the first instance decision
that the Utility Model was invalid. The decision has only a declaratory effect, as the Utility Model had expired in November 2015.
On April 28, 2020, the Company filed a withdrawal on the complaint on the German utility model, thereby waiving its claims on
these proceedings. The Company estimates that the expense will be less than €40,000.
CORMEDIX
INC. AND SUBSIDIARY
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
In
October 2016, TauroPharm submitted a further writ to the EPO requesting a date for the hearing and bringing forward further arguments,
in particular in view of the June 2016 decision of the German PTO on the invalidity of the utility model. On November 22, 2017,
the EPO in Munich, Germany held a further oral hearing in this matter. At the hearing, the panel held that the Prosl European
Patent would be invalidated because it did not meet the requirements of novelty based on a technical aspect of the European intellectual
property law. The Company disagrees with this decision and, after the written opinion was issued by the Opposition Division in
September 2018, has appealed the decision. The Company continues to believe that the Prosl European Patent is indeed novel and
that its validity should be maintained. There can be no assurance that the Company will prevail in this matter. In addition, the
ongoing Unfair Competition litigation brought by the Company against TauroPharm is not affected and will continue.
On
January 16, 2015, the Company filed a complaint against TauroPharm GmbH and its managing directors in the District Court
of Cologne, Germany. In the complaint, the Company alleges violation of the German Unfair Competition Act by TauroPharm
for the unauthorized use of its proprietary information obtained in confidence by TauroPharm. The Company alleges that
TauroPharm is improperly and unfairly using its proprietary information relating to the composition and manufacture of Neutrolin,
in the manufacture and sale of TauroPharm’s products TauroLockTM, TauroLock-HEP100 and TauroLock-HEP500. The
Company seeks a cease and desist order against TauroPharm from continuing to manufacture and sell any product containing taurolidine
(the active pharmaceutical ingredient (“API”) of Neutrolin) and citric acid in addition to possible other components,
damages for any sales in the past and the removal of all such products from the market. An initial hearing in the District
Court of Cologne, Germany was held on November 19, 2015 to consider the Company’s claims. In this hearing, the presiding
judge explained that the court needed more information with regard to several aspects of the case. As a consequence, the Court
issued an interim decision in the form of a court order outlining several issues of concern that relate primarily to the court's
interest in clarifying the facts and reviewing any and all available documentation, in particular with regard to the question
which specific know-how was provided to TauroPharm by whom and when. The Company's legal team prepared the requested reply and
produced the respective documentation. TauroPharm had also filed another writ within the same deadline and both parties have filed
further writs at the end of April 2016 setting out their respective argumentation in more detail. A further oral hearing in this
matter was held on November 15, 2016. In this hearing, the court heard arguments from CorMedix and TauroPharm concerning the allegations
of unfair competition. The Court made no rulings from the bench and indicated that it is prepared to further examine the underlying
facts of the Company's allegations. On March 7, 2017, the Court issued another interim decision in the form of a court order outlining
again several issues relating to the argumentation of both sides in the proceedings. In particular the court requested the Company
to further specify its requests and to further substantiate in even more detail which know-how was provided by Biolink (the company
who developed Neutrolin that was acquired by ND Partners) to TauroPharm by whom and when. The Court also raised the question whether
the know-how provided at the time to TauroPharm could still be considered to be secret know-how or may have become public in the
meantime. The Court granted both sides the opportunity to reply to this court order and provide additional facts and evidence
until May 15, 2017. Both parties have submitted further writs in this matter and the Court scheduled a further hearing on May
8, 2018. After having been rescheduled several times, the hearing took place on November 20, 2018. A decision was rendered by
the court on December 11, 2018, dismissing the complaint in its entirety. However, the Company intends to continue to pursue this
matter, and still believes firmly that its claims are well-founded. The Company therefore appealed in January 2019 and filed its
grounds of appeal in March 2019. An oral hearing was held on September 6, 2019 in which the legal counsel of the Company brought
forward further arguments for the fact that the manufacturing process of the respective catheter locking solution is indeed protectable
as a trade secret. In view of these new arguments, the Court issued an evidentiary order on September 27, 2019 ordering an expert
opinion. The expert opinion was not in the Company's favor but the Company has filed a response to the expert opinion in reaction
to which the Court asked the expert to supplement his opinion to address the issues brought forward in the Company's submission.
Next steps will be taken after the receipt of the supplementary expert opinion.
CORMEDIX
INC. AND SUBSIDIARY
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
In
connection with the aforementioned patent and utility model infringement and unfair competition proceedings against TauroPharm,
the Company was required by the District Courts of Mannheim and Cologne to provide security deposits of an aggregate of approximately
$170,000, to cover legal fees in the event TauroPharm is entitled to reimbursement of these costs. The
Company recorded the deposits as restricted cash on the consolidated balance sheets.
Commitments
In-Licensing
In
2008, the Company entered into a License and Assignment Agreement (the “NDP License Agreement”) with ND Partners,
LLP (“NDP”). Pursuant to the NDP License Agreement, NDP granted the Company exclusive, worldwide licenses for certain
antimicrobial catheter lock solutions, processes for treating and inhibiting infections, a biocidal lock system and a taurolidine
delivery apparatus, and the corresponding United States and foreign patents and applications (the “NDP Technology”).
The Company acquired such licenses and patents through its assignment and assumption of NDP’s rights under certain separate
license agreements by and between NDP and Dr. Hans-Dietrich Polaschegg, Dr. Klaus Sodemann and Dr. Johannes Reinmueller. As consideration
in part for the rights to the NDP Technology, the Company paid NDP an initial licensing fee of $325,000 and granted NDP a 5% equity
interest in the Company, consisting of 7,996 shares of the Company’s common stock.
The
Company is required to make payments to NDP upon the achievement of certain regulatory and sales-based milestones. Certain of
the milestone payments are to be made in the form of shares of common stock currently held in escrow for NDP, and other milestone
payments are to be paid in cash. The maximum aggregate number of shares issuable upon achievement of milestones is 29,109 shares.
In 2014, a certain milestone was achieved resulting in the release of 7,277 shares held in escrow. The number of shares held in
escrow as of March 31, 2020 is 21,832 shares of common stock. The maximum aggregate amount of cash payments due upon achievement
of milestones is $3,000,000 with the balance being $2,500,000 as of March 31, 2020 and 2019. Events that trigger milestone payments
include but are not limited to the reaching of various stages of regulatory approval and upon achieving certain worldwide net
sales amounts. There were no milestones achieved during the quarters ended March 31, 2020 and 2019.
The
NDP License Agreement may be terminated by the Company on a country-by-country basis upon 60 days prior written notice. If the
NDP License Agreement is terminated by either party, the Company’s rights to the NDP Technology will revert back to NDP.
Note
5 — Leases:
The Company entered into a seven-year operating
lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement,
with a monthly average cost of approximately $17,000, is expected to commence in the third quarter of 2020 upon the Company’s
occupation of the premises.
The
Company entered into an operating lease for office space in Germany that began in July 2017. The rental agreement has a three-month
term which automatically renews and includes a monthly cost of 400 Euros. The Company elected to apply the short-term practical
expedient to the office lease. The Company also has an operating lease for office equipment.
CORMEDIX
INC. AND SUBSIDIARY
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Operating
lease expense in the Company’s condensed consolidated statements of operations and comprehensive loss for each of the three
months ended March 31, 2020 and 2019 was approximately $2,000, which includes costs associated with leases for which ROU assets
have been recognized as well as short-term leases.
At
March 31, 2020, the Company has a total operating lease liability of $3,500. Approximately $1,500 and $2,000, respectively, are
included in accrued expenses and operating lease liabilities, net of current portion on the condensed consolidated balance sheet.
Operating ROU assets as of March 31, 2020 are $4,000 and are included in property and equipment, net on the condensed consolidated
balance sheet.
For
each of the three months ended March 31, 2020 and 2019, cash paid for amounts included in the measurement of lease liabilities
in operating cash flows from operating leases was $2,000.
The
weighted average remaining lease term as of March 31, 2020 and 2019 were 2.3 and 2.8 years, respectively, and the weighted average
discount rate for operating leases was 10.0% each as of March 31, 2020 and 2019.
As
of March 31, 2020, maturities of lease liabilities were as follows:
2020 (excluding the three months ended March 31, 2020)
|
|
$
|
1,500
|
|
2021
|
|
|
2,000
|
|
2022
|
|
|
1,000
|
|
Total future minimum lease payments
|
|
|
4,500
|
|
Less imputed interest
|
|
|
(1,000
|
)
|
Total
|
|
$
|
3,500
|
|
Note
6 — Concentrations:
At
March 31, 2020, 95% of net accounts receivable was due from three customers that exceeded 10% of the Company’s accounts
receivable (40%, 40% and 15%) and at December 31, 2019, no net accounts receivable was due from a customer that exceeded 10% of
the Company’s accounts receivable. During the three months ended March 31, 2020 and 2019, the Company had revenue from three
customers that exceeded 10% of its total sales, 62%, 19% and 10% in 2020, and 64%, 19% and 10%, in for the same period in 2019.